These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 25519989)

  • 1. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
    Chio CM; Lim CS; Bishop AC
    Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases.
    Chio CM; Yu X; Bishop AC
    Bioorg Med Chem; 2015 Jun; 23(12):2828-38. PubMed ID: 25828055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Allosteric Site on SHP2's Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules.
    Marsh-Armstrong B; Fajnzylber JM; Korntner S; Plaman BA; Bishop AC
    ACS Omega; 2018 Nov; 3(11):15763-15770. PubMed ID: 30533581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric modulation of SHP2: Quest from known to unknown.
    Wang N; Zhu S; Lv D; Wang Y; Khawar MB; Sun H
    Drug Dev Res; 2023 Nov; 84(7):1395-1410. PubMed ID: 37583266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
    Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
    J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
    Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
    Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
    Kim JY; Plaman BA; Bishop AC
    Biochemistry; 2020 Sep; 59(37):3498-3507. PubMed ID: 32871078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized allosteric inhibition of engineered protein tyrosine phosphatases with an expanded palette of biarsenical small molecules.
    Korntner S; Pomorski A; Krężel A; Bishop AC
    Bioorg Med Chem; 2018 May; 26(9):2610-2620. PubMed ID: 29673715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct Chemical Activation of a Rationally Engineered Signaling Enzyme.
    Chio CM; Cheng KW; Bishop AC
    Chembiochem; 2015 Aug; 16(12):1735-9. PubMed ID: 26063205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
    Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
    J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
    Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
    J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
    Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
    Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
    Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
    Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
    Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
    Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2-EGFR States in Dephosphorylation Can Inform Selective SHP2 Inhibitors, Dampening RasGAP Action.
    Liu Y; Jang H; Nussinov R
    J Phys Chem B; 2024 May; 128(21):5175-5187. PubMed ID: 38747619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization.
    Buck SJS; Plaman BA; Bishop AC
    ACS Omega; 2022 Apr; 7(16):14180-14188. PubMed ID: 35559188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
    Jin WY; Ma Y; Li WY; Li HL; Wang RL
    Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
    Yuan X; Bu H; Zhou J; Yang CY; Zhang H
    J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.